Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
April 12 2022 - 8:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced the appointments of Gwen
Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice
President of Affinity Reagent Development, adding further
experience to its senior leadership team in its ongoing expansion
of the organization.
Gwen Weld, Chief People Officer
Gwen Weld brings to Nautilus more than 25 years of senior
leadership in human resources, organizational culture, and business
strategy. Immediately prior to joining the company, Ms. Weld served
as Interim Chief People Officer at Amperity. She previously held
the positions of Vice President of Global People and Infrastructure
at Isilon Systems for more than six years and General Manager of
Human Resources at Microsoft Corporation for nearly twenty years,
leading Microsoft’s human resources agenda for its various groups
and overseeing worldwide recruiting and alternative staffing. Ms.
Weld studied business administration at Pace University.
“Gwen’s breadth and depth of experience makes her
extraordinarily well-suited to help us scale out a world-class
team, deepen our high-performance culture, and do so in a way that
creates an inclusive, driven, and highly collaborative work
environment at Nautilus,” said Sujal Patel, co-founder and CEO of
Nautilus. “I am thrilled to work with Gwen as we prioritize
building a people-first culture that supports our growing teams as
they deliver transformative technologies into the world.”
Sheri Wilcox, Ph.D., Vice President of Affinity Reagent
Development
Sheri Wilcox, Ph.D., joins Nautilus from SomaLogic, where she
was instrumental in the development of the SomaScan Platform and
SOMAmer reagents over 21 years at the company and most recently
served as Senior Director of Global Scientific Engagement. Dr.
Wilcox advanced through positions of increasing responsibility at
SomaLogic, including Associate Director of Aptamer Discovery where
she guided research of aptamers for biomarker discovery and
directed the high-throughput generation of SOMAmer reagents, and
Senior Director of Analytical and Discovery Sciences, leading
SOMAmer discovery and characterization efforts, as well as several
collaborations. Before joining SomaLogic, she applied mass
spectrometric methods to understanding antibiotic resistance as a
postdoctoral fellow at Pharmacia, prior to its merger with Pfizer
Inc. Dr. Wilcox received her B.S. in chemistry from Vanderbilt
University, and her Ph.D. in macromolecular and cellular structure
and chemistry from Scripps Research.
“Dr. Wilcox is a renowned protein scientist who has been a
driving force behind the acceleration of emerging proteomic
technologies,” said Parag Mallick, Ph.D., co-founder and Chief
Scientist of Nautilus. “Her decades of research advancing human
proteomics and communicating its potential to improve healthcare
not only aligns with, but strengthens our vision to democratize
access to the proteome and enable the development of innovative
diagnostics and therapeutics. We are excited to welcome her to our
team.”
About Nautilus Biotechnology, Inc.With its
corporate headquarters in Seattle and its research and development
headquarters in the San Francisco Bay Area, Nautilus is a
development stage life sciences company creating a platform
technology for quantifying and unlocking the complexity of the
proteome. Nautilus’ mission is to transform the field of proteomics
by democratizing access to the proteome and enabling fundamental
advancements across human health and medicine. To learn more about
Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of federal securities laws.
Forward-looking statements in this press release include, but are
not limited to, statements regarding Nautilus’ expectations with
respect to the suitability of the Nautilus product platform to
investigate proteins and proteoforms; and expectations with respect
to the functionality and performance of Nautilus’ product platform,
its potential impact on pharmaceutical development and drug
discovery; and the ability of management personnel to contribute to
the execution of Nautilus’ strategic plans and goals. These
statements are based on numerous assumptions concerning the
development of Nautilus’ products and target markets and involve
substantial risks, uncertainties and other factors that may cause
actual results to be materially different from the information
expressed or implied by these forward-looking statements. Risks and
uncertainties that could materially affect the accuracy of
Nautilus’ assumptions and its ability to achieve the
forward-looking statements set forth in this press release include
(without limitation) the following: Nautilus’ product platform is
not yet commercially available and remains subject to significant
scientific and technical development, which is inherently
challenging and difficult to predict, particularly with respect to
highly novel and complex products such as those being developed by
Nautilus. Even if our development efforts are successful, our
product platform will require substantial validation of its
functionality and utility in life science research. In the course
of Nautilus’ scientific and technical development and associated
product validation and commercialization, we may experience
material delays as a result of unanticipated events. We cannot
provide any guarantee or assurance with respect to the outcome of
our development, collaboration, and commercialization initiatives
or with respect to their associated timelines. For a more detailed
description of additional risks and uncertainties facing Nautilus
and its development efforts, investors should refer to the
information under the caption “Risk Factors” in the Registration
Statement on Form S-1 filed with the SEC as well as in our Annual
Report on Form 10-K filed for the year ended December 31, 2021. The
forward-looking statements in this press release are as of the date
of this press release. Except as otherwise required by applicable
law, Nautilus disclaims any duty to update any forward-looking
statements. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Disclosure InformationNautilus uses filings
with the Securities and Exchange Commission, its website
(www.nautilus.bio), press releases, public conference calls, public
webcasts, and its social media accounts as means of disclosing
material non-public information and for complying with Regulation
FD. Therefore, Nautilus encourages investors, the media, and others
interested in Nautilus to review the information it makes public in
these locations, as such information could be deemed to be material
information.
Media Contactpress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/868bb0f4-15b6-48f2-89c2-f4e9a5f5133e
https://www.globenewswire.com/NewsRoom/AttachmentNg/efe32343-2e60-4151-ad08-2aa4ef6879a0
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Apr 2023 to Apr 2024